---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-126584"
form_type: "8-K"
ticker: "ADVB"
cik: "0001941029"
company_name: "Advanced Biomed Inc."
filed_at: "2025-12-30T23:59:59+00:00"
generated_at: "2026-05-16T12:01:46.022043+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan

## Summary
- Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.
- Transaction closed on December 23, 2025; board unanimously approved.
- CEO cites evolving China regulatory requirements on clinical trials and data as reason for divestiture.
- All clinical trials will now be centralized and conducted through the Taiwan subsidiary.
- Buyer Wei Ha Hui is an unrelated third party.

## SEC filing metadata
- accession: 0001213900-25-126584
- form_type: 8-K
- ticker: ADVB
- cik: 0001941029
- company_name: Advanced Biomed Inc.
- filed_at: 2025-12-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/ea0271157-8k_advanced.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-126584
- JSON: https://secwatch.observer/filing/0001213900-25-126584.json
- Plain text: https://secwatch.observer/filing/0001213900-25-126584.txt

## Key facts
- M&A Transactions
  Advanced Biomed Inc. completed a disposition involving Wei Ha Hui for US$23,000 (closed 2025-12-23).
  - Action: disposition
  - Counterparty: Wei Ha Hui
  - Consideration: US$23,000
  - Closing: 2025-12-23
  source text: ntered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm
- Material Agreements
  Advanced Biomed Inc. entered into Share Purchase Agreement with Wei Ha Hui valued at Purchase price of US$23,000 for 100% of Advanced Biomed (HK) Limited (effective 2025-12-23).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Wei Ha Hui
  - Value: Purchase price of US$23,000 for 100% of Advanced Biomed (HK) Limited
  - Effective: 2025-12-23
  source text: On December 23, 2025, Advanced Biomed Inc. (the “ Company ”) entered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “ Hong Kong Subsidiary ”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.